The mechanism of cancer cell death by PARP inhibitors goes beyond DNA damage alone

被引：6
|
作者：
Maccio, Antonio [1 ]
Madeddu, Clelia [2 ]
机构：
[1] Azienda Osped Brotzu, Dept Gynecol Oncol, Via Jenner, I-09120 Cagliari, Italy
[2] Univ Cagliari, Dept Med Sci & Publ Hlth, Cagliari, Italy
来源：
INTERNATIONAL JOURNAL OF CANCER | 2019年 / 145卷 / 09期
关键词：
POLYMERASE; OLAPARIB;
D O I：
10.1002/ijc.32392
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2594 / 2596
页数：3
相关论文
共 50 条
  • [21] Beyond PARP Inhibitors: Agents in Pipelines Target DNA Repair Mechanisms
    Maxmen, Amy
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (15) : 1110 - 1111
  • [22] DNA damage response mutations enhance the antitumor efficacy of ATR and PARP inhibitors in cholangiocarcinoma cell lines
    Lerksuthirat, Tassanee
    Prasopporn, Sunisa
    Wikiniyadhanee, Rakkreat
    Chitphuk, Sermsiri
    Stitchantrakul, Wasana
    Owneium, Paravee
    Jirawatnotai, Siwanon
    Dejsuphong, Donniphat
    ONCOLOGY LETTERS, 2025, 29 (03)
  • [23] New Insights into PARP Inhibitors' Effect on Cell Cycle and Homology-Directed DNA Damage Repair
    Jelinic, Petar
    Levine, Douglas A.
    MOLECULAR CANCER THERAPEUTICS, 2014, 13 (06) : 1645 - 1654
  • [24] PARP inhibitors trap PARP2 and alter the mode of recruitment of PARP2 at DNA damage sites
    Lin, Xiaohui
    Jiang, Wenxia
    Rudolph, Johannes
    Lee, Brian J.
    Luger, Karolin
    Zha, Shan
    NUCLEIC ACIDS RESEARCH, 2022, 50 (07) : 3958 - 3973
  • [25] A two-step mechanism governing PARP1-DNA retention by PARP inhibitors
    Xue, Huijun
    Bhardwaj, Amit
    Yin, Yandong
    Fijen, Carel
    Ephstein, Anastasiya
    Zhang, Lianglin
    Ding, Xia
    Pascal, John M.
    VanArsdale, Todd L.
    Rothenberg, Eli
    SCIENCE ADVANCES, 2022, 8 (36)
  • [26] DNA damage responses: Cancer and beyond
    Kastan, MB
    SCIENTIST, 2005, 19 (19): : 24 - 25
  • [27] DNA Damage Response Inhibitors Potentiate Immunogenic Cell Death and Radiotherapy in Merkel Cell Carcinoma
    Goff, Peter
    Bhakuni, Rashmi
    Pulliam, Thomas
    Rengan, Ramesh
    Nghiem, Paul
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2021, 44 (10): : S19 - S19
  • [28] Clinical PARP inhibitors do not abrogate PARP1 exchange at DNA damage sites in vivo
    Shao, Zhengping
    Lee, Brian J.
    Rouleau-Turcotte, Elise
    Langelier, Marie-France
    Lin, Xiaohui
    Estes, Verna M.
    Pascal, John M.
    Zha, Shan
    NUCLEIC ACIDS RESEARCH, 2020, 48 (17) : 9694 - 9709
  • [29] PARP Inhibitors in BRCA Gene-Mutated Ovarian Cancer and Beyond
    Banerjee, Susana
    Kaye, Stan
    CURRENT ONCOLOGY REPORTS, 2011, 13 (06) : 442 - 449
  • [30] Progress in PARP inhibitors beyond BRCA mutant recurrent ovarian cancer?
    Gonzalez Martin, Antonio
    LANCET ONCOLOGY, 2017, 18 (01): : 8 - 9
12345